As the legal cannabis industry continues to expand to nearly every corner of the planet, the variety of products available to medical cannabis patients is also expanding. Raw medical cannabis flower is still popular in many jurisdictions, however, patient demand and regulatory parameters are driving product innovation, particularly at the international level.
A great example of that can be found in Australia, Germany, and the United Kingdom where multi-country operator SOMAÍ Pharmaceuticals recently introduced its proprietary Mint Oral Solutions product line.
“The new line includes single-strain oils infused with peppermint terpene mixes in various dosage forms, from CBD-dominant to balanced and high-THC. The mint line is the first introduction to improve patients’ compliance and treatment adherence, combining purified extracts and a subtle aromatic mint taste.” SOMAÍ Pharmaceuticals stated about its new product line.
“Cannabis patients prioritize the products’ performance, smell, and taste,” said Michael Sassano, the founder and interim CEO of SOMAI Pharmaceuticals. “So as we prioritize improving patient experience, mint is an excellent starting experience as a popular blend with calming and therapeutic effects, as well as a pleasant subtle taste.”
Currently, the international cannabis industry is a patchwork of laws, rules, and regulations. As such, each market has its own nuances and limitations regarding which types of products can be sold. That, in turn, results in the introduction of new products as entrepreneurs and innovators come up with fresh ideas for products to meet evolving demand.
According to a recent study conducted by researchers from Ukraine and France, and published by the U.S. National Institute of Health, 57 countries have adopted medical cannabis legalization measures. The spread of global medical cannabis policy reform is being matched by a rise in the worldwide industry’s market potential.
For example, the global cannabis pharmaceuticals sector alone is projected to reach $102.4 billion by 2030, expanding at a CAGR of 53.3% from 2024 to 2030, according to a recent analysis by Research and Markets.
“In 2023, Europe dominated the overall market with a revenue share of 41.9% owing to increasing cannabis consumption, as well as rising awareness and positive attitude towards cannabis and its products.” stated Research and Markets in its analysis.
A separate global CBD market analysis conducted by Grand View Research found that the global CBD market was worth $7.7 billion in 2023, and estimates that the market will grow by 15.8% from 2024 to 2030.
This article first appeared on Internationalcbc.com and is syndicated here with special permission.
Photo by Cova Software on Unsplash
